Luminy Entreprises, case 923, 163 Av. de Luminy
13288 Marseille cedex 9
Phone: +33 4 91 29 30 90
Fax: +33 4 91 29 30 99
IPSOGEN is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancer. IPSOGEN has built a comprehensive portfolio of unique products in blood cancers available in over 50 countries all over the world to leading institutions involved in cancer care. For example, we are the worldwide exclusive licensee for the JAK2 V617F mutation and offer both kits and customized services for the identification and the quantification of this mutation, which can be used for the screening and the follow-up of patients with myeloproliferative disorders. Leveraging its expertise in blood cancers, IPSOGEN has developed, in partnership with leading cancer institutions, a pipeline of diagnostic products in breast cancer. At the clinical level, we also act as a molecular CRO for several pharmaceutical companies to support their clinical trials in oncology. Our services include sample procurement and standardised collection, secured and adapted sample shipment for multicentric trials, nucleic acid extraction, gene expression and/or genotyping analysis in a GLP-compliant setting. IPSOGEN is headquartered in Marseille, France and has its U.S. offices in New Haven, Connecticut.